What is Pacific Biosc's earnings per share (EPS)?

Pacific Biosc (PACB) reported diluted earnings per share of $-1.82 for fiscal year 2025. This represents a -14.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Pacific Biosc Financials

PACB

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Pacific Biosc (PACB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 23/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Pacific Biosc has an operating margin of -346.1%, meaning the company retains $-346 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -308.0% the prior year.

Growth

Pacific Biosc's revenue grew a modest 3.9% year-over-year to $160.0M. This slow but positive growth earns a score of 40/100.

Leverage

Pacific Biosc has elevated debt relative to equity (D/E of 145.59), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

100

With a current ratio of 5.15, Pacific Biosc holds $5.15 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

While Pacific Biosc generated -$111.2M in operating cash flow, capex of $2.7M consumed most of it, leaving -$113.9M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Pacific Biosc generates a -10214.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -61.2% the prior year.

Piotroski F-Score Weak

3/9

Pacific Biosc passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

0.20x

For every $1 of reported earnings, Pacific Biosc generates $0.20 in operating cash flow (-$111.2M OCF vs -$546.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-79.6x

Pacific Biosc earns $-79.6 in operating income for every $1 of interest expense (-$553.9M vs $7.0M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$160.0M

YoY+3.9%

5Y CAGR+15.2%

10Y CAGR+5.6%

Pacific Biosc generated $160.0M in revenue in fiscal year 2025. This represents an increase of 3.9% from the prior year.

EBITDA

-$171.4M

YoY+60.4%

Pacific Biosc's EBITDA was -$171.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 60.4% from the prior year.

Net Income

-$546.4M

YoY-76.3%

Pacific Biosc reported -$546.4M in net income in fiscal year 2025. This represents a decrease of 76.3% from the prior year.

EPS (Diluted)

$-1.82

YoY-14.5%

Pacific Biosc earned $-1.82 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 14.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$113.9M

YoY+46.3%

Pacific Biosc generated -$113.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 46.3% from the prior year.

Cash & Debt

$63.7M

YoY+15.1%

5Y CAGR-4.8%

10Y CAGR+6.6%

Pacific Biosc held $63.7M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

$0.00

Pacific Biosc paid $0.00 per share in dividends in fiscal year 2025.

Shares Outstanding

302M

YoY+2.6%

5Y CAGR+9.4%

10Y CAGR+14.2%

Pacific Biosc had 302M shares outstanding in fiscal year 2025. This represents an increase of 2.6% from the prior year.

Margins & Returns

Gross Margin

28.6%

YoY+4.4pp

5Y CAGR-12.7pp

10Y CAGR-29.0pp

Pacific Biosc's gross margin was 28.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 4.4 percentage points from the prior year.

Operating Margin

-346.1%

YoY-38.2pp

5Y CAGR-213.8pp

10Y CAGR-314.8pp

Pacific Biosc's operating margin was -346.1% in fiscal year 2025, reflecting core business profitability. This is down 38.2 percentage points from the prior year.

Net Margin

-341.5%

YoY-140.3pp

5Y CAGR-378.7pp

10Y CAGR-307.3pp

Pacific Biosc's net profit margin was -341.5% in fiscal year 2025, showing the share of revenue converted to profit. This is down 140.3 percentage points from the prior year.

Return on Equity

-10214.5%

YoY-10153.4pp

5Y CAGR-10223.3pp

10Y CAGR-10171.4pp

Pacific Biosc's ROE was -10214.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 10153.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$97.3M

YoY-27.9%

5Y CAGR+8.7%

10Y CAGR+4.9%

Pacific Biosc invested $97.3M in research and development in fiscal year 2025. This represents a decrease of 27.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$2.7M

YoY-56.1%

5Y CAGR+21.2%

10Y CAGR-1.0%

Pacific Biosc invested $2.7M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 56.1% from the prior year.

PACB Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$160.0M+3.9%	$154.0M-23.2%	$200.5M+56.3%	$128.3M-1.7%	$130.5M+65.4%	$78.9M
Cost of Revenue	$114.2M-2.1%	$116.7M-21.0%	$147.7M+86.4%	$79.3M+10.6%	$71.7M+54.7%	$46.3M
Gross Profit	$45.8M+22.8%	$37.3M-29.4%	$52.8M+7.6%	$49.0M-16.7%	$58.9M+80.7%	$32.6M
R&D Expenses	$97.3M-27.9%	$134.9M-27.9%	$187.2M-3.0%	$193.0M+70.9%	$112.9M+76.0%	$64.2M
SG&A Expenses	$141.5M-19.2%	$175.0M+3.1%	$169.8M+5.6%	$160.9M+29.6%	$124.1M+70.5%	$72.8M
Operating Income	-$553.9M-16.8%	-$474.3M-41.8%	-$334.5M-8.9%	-$307.2M-46.0%	-$210.4M-101.6%	-$104.4M
Interest Expense	$7.0M-48.2%	$13.4M-6.5%	$14.3M-2.4%	$14.7M+17.2%	$12.5M+4592.9%	$267K
Income Tax	$318K+0.6%	$316K+102.8%	-$11.4M	$0+100.0%	-$93.6M	N/A
Net Income	-$546.4M-76.3%	-$309.9M-1.0%	-$306.7M+2.4%	-$314.2M-73.4%	-$181.2M-716.3%	$29.4M
EPS (Diluted)	$-1.82-14.5%	$-1.59-31.4%	$-1.21+13.6%	$-1.40-57.3%	$-0.89-623.5%	$0.17

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$44.6M+16.1%	$38.4M-3.3%	$39.8M+7.0%	$37.2M-5.3%	$39.2M-1.9%	$40.0M+11.0%	$36.0M-7.2%	$38.8M
Cost of Revenue	$28.1M+24.6%	$22.5M-10.1%	$25.1M-34.9%	$38.5M+32.1%	$29.2M-2.7%	$30.0M-0.4%	$30.1M+9.3%	$27.5M
Gross Profit	$16.6M+4.2%	$15.9M+8.3%	$14.7M+1171.0%	-$1.4M-113.6%	$10.1M+0.5%	$10.0M+68.5%	$5.9M-47.4%	$11.3M
R&D Expenses	$22.9M+0.1%	$22.8M+1.4%	$22.5M-22.5%	$29.1M+5.8%	$27.5M+7.6%	$25.5M-33.7%	$38.5M-11.4%	$43.5M
SG&A Expenses	$34.1M+9.5%	$31.1M-14.0%	$36.2M-9.9%	$40.2M-3.5%	$41.6M-4.8%	$43.7M-4.6%	$45.9M+4.9%	$43.8M
Operating Income	-$41.2M-6.0%	-$38.9M+13.3%	-$44.9M+89.5%	-$428.9M-180.3%	-$153.0M-138.8%	-$64.1M+63.6%	-$175.8M-116.1%	-$81.4M
Interest Expense	$1.7M+0.1%	$1.7M+0.1%	$1.7M+0.1%	$1.7M-37.0%	$2.8M-22.1%	$3.5M-0.1%	$3.5M-0.9%	$3.6M
Income Tax	$202K-47.3%	$383K+994.3%	$35K+111.6%	-$302K-195.6%	$316K	$0	$0	$0
Net Income	-$40.4M-6.2%	-$38.0M+9.4%	-$41.9M+90.2%	-$426.1M-18070.3%	$2.4M+103.9%	-$60.7M+65.0%	-$173.3M-121.7%	-$78.2M
EPS (Diluted)	N/A	$-0.13+7.1%	$-0.14+90.3%	$-1.44	N/A	$-0.22+65.6%	$-0.64-120.7%	$-0.29

PACB Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$784.1M-37.8%	$1.3B-27.8%	$1.7B-1.2%	$1.8B-12.0%	$2.0B+384.8%	$414.0M
Current Assets	$375.1M-24.3%	$495.7M-33.2%	$742.0M-12.9%	$852.1M-22.6%	$1.1B+209.7%	$355.6M
Cash & Equivalents	$63.7M+15.1%	$55.4M-69.2%	$179.9M-44.7%	$325.1M-29.4%	$460.7M+464.5%	$81.6M
Inventory	$49.3M-16.1%	$58.8M+3.7%	$56.7M+12.5%	$50.4M+104.8%	$24.6M+72.9%	$14.2M
Accounts Receivable	$35.4M+28.8%	$27.5M-24.8%	$36.6M+94.9%	$18.8M-22.5%	$24.2M+44.0%	$16.8M
Goodwill	$317.8M0.0%	$317.8M-31.3%	$462.3M+12.8%	$410.0M0.0%	$410.0M	N/A
Total Liabilities	$778.7M+3.3%	$753.9M-27.8%	$1.0B-13.2%	$1.2B-1.0%	$1.2B+1449.2%	$78.5M
Current Liabilities	$72.8M+9.9%	$66.3M-30.2%	$95.0M-63.9%	$263.3M+267.2%	$71.7M+86.2%	$38.5M
Long-Term Debt	N/A	N/A	N/A	$896.7M+0.1%	$896.1M	N/A
Total Equity	$5.3M-98.9%	$506.6M-27.8%	$701.3M+24.6%	$562.9M-28.8%	$791.0M+135.8%	$335.5M
Retained Earnings	-$2.7B-25.4%	-$2.1B-16.8%	-$1.8B-20.0%	-$1.5B-25.8%	-$1.2B-17.5%	-$1.0B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$784.1M-2.4%	$803.2M-2.7%	$825.5M-4.1%	$860.8M-31.7%	$1.3B-13.1%	$1.5B-3.9%	$1.5B-9.6%	$1.7B
Current Assets	$375.1M-4.9%	$394.2M-4.6%	$413.4M-7.1%	$444.9M-10.2%	$495.7M-15.2%	$584.2M-7.0%	$628.1M-7.2%	$677.0M
Cash & Equivalents	$63.7M+12.8%	$56.5M+3.0%	$54.8M-6.3%	$58.5M+5.7%	$55.4M-29.0%	$78.0M-21.6%	$99.5M+29.9%	$76.6M
Inventory	$49.3M-7.3%	$53.2M-1.3%	$53.8M-0.3%	$54.0M-8.1%	$58.8M-10.6%	$65.7M-4.2%	$68.6M+1.9%	$67.3M
Accounts Receivable	$35.4M+15.8%	$30.6M-5.1%	$32.3M+1.9%	$31.6M+15.0%	$27.5M-6.3%	$29.4M-9.4%	$32.4M+7.0%	$30.3M
Goodwill	$317.8M0.0%	$317.8M0.0%	$317.8M0.0%	$317.8M0.0%	$317.8M-13.9%	$369.1M0.0%	$369.1M-20.2%	$462.3M
Total Liabilities	$778.7M+1.5%	$767.1M+0.4%	$764.0M-0.7%	$769.2M+2.0%	$753.9M-24.4%	$996.9M-2.0%	$1.0B-0.4%	$1.0B
Current Liabilities	$72.8M+15.2%	$63.2M+5.8%	$59.8M-10.3%	$66.6M+0.5%	$66.3M+10.5%	$60.0M-23.5%	$78.4M+7.5%	$73.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$5.3M-85.2%	$36.1M-41.3%	$61.5M-32.9%	$91.6M-81.9%	$506.6M+11.8%	$453.1M-8.0%	$492.7M-24.1%	$649.0M
Retained Earnings	-$2.7B-1.5%	-$2.7B-1.5%	-$2.6B-1.6%	-$2.6B-19.8%	-$2.1B+0.1%	-$2.2B-2.9%	-$2.1B-9.0%	-$1.9B

PACB Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$111.2M+46.0%	-$206.1M+20.5%	-$259.2M+1.5%	-$263.2M-136.7%	-$111.2M-670.1%	$19.5M
Capital Expenditures	$2.7M-56.1%	$6.2M-30.0%	$8.8M-47.2%	$16.8M+182.4%	$5.9M+470.8%	$1.0M
Free Cash Flow	-$113.9M+46.3%	-$212.2M+20.8%	-$268.0M+4.3%	-$280.0M-139.1%	-$117.1M-734.3%	$18.5M
Investing Cash Flow	$115.4M-6.9%	$124.0M+2593.4%	$4.6M-96.0%	$116.1M+117.1%	-$678.5M-209.4%	-$219.3M
Financing Cash Flow	$3.4M+108.0%	-$43.0M-139.5%	$108.9M+1031.7%	$9.6M-99.2%	$1.2B+364.4%	$251.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$19.1M-1.9%	-$18.7M+36.3%	-$29.4M+33.3%	-$44.1M-43.7%	-$30.6M+32.6%	-$45.5M+16.2%	-$54.3M+28.3%	-$75.7M
Capital Expenditures	$861K+1101.2%	-$86K-115.6%	$550K-60.4%	$1.4M-14.1%	$1.6M+305.5%	-$787K-153.2%	$1.5M-61.9%	$3.9M
Free Cash Flow	-$19.9M-6.1%	-$18.8M+37.2%	-$29.9M+34.1%	-$45.4M-40.8%	-$32.3M+30.2%	-$46.3M+17.0%	-$55.7M+29.9%	-$79.6M
Investing Cash Flow	$26.0M+37.7%	$18.9M-25.2%	$25.3M-44.1%	$45.2M-22.3%	$58.2M+152.5%	$23.1M-70.0%	$76.8M+325.1%	-$34.1M
Financing Cash Flow	$0-100.0%	$1.5M	$0-100.0%	$2.0M+103.9%	-$50.2M-6282.3%	$812K+634.2%	-$152K-102.3%	$6.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

PACB Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	28.6%+4.4pp	24.2%-2.1pp	26.3%-11.9pp	38.2%-6.9pp	45.1%+3.8pp	41.3%
Operating Margin	-346.1%-38.2pp	-308.0%-141.2pp	-166.8%+72.6pp	-239.4%-78.2pp	-161.2%-28.9pp	-132.3%
Net Margin	-341.5%-140.3pp	-201.2%-48.2pp	-153.0%+91.9pp	-244.9%-106.1pp	-138.8%-176.1pp	37.3%
Return on Equity	-10214.5%-10153.4pp	-61.2%-17.4pp	-43.7%+12.1pp	-55.8%-32.9pp	-22.9%-31.7pp	8.8%
Return on Assets	-69.7%-45.1pp	-24.6%-7.0pp	-17.6%+0.2pp	-17.8%-8.8pp	-9.0%-16.1pp	7.1%
Current Ratio	5.15-2.3	7.48-0.3	7.81+4.6	3.24-12.1	15.36+6.1	9.24
Debt-to-Equity	145.59+144.1	1.490.0	1.49-0.1	1.59+0.5	1.13+0.9	0.23
FCF Margin	-71.2%+66.6pp	-137.8%-4.2pp	-133.7%+84.5pp	-218.2%-128.5pp	-89.7%-113.1pp	23.4%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	37.1%-4.3pp	41.4%+4.4pp	36.9%+40.6pp	-3.7%-29.3pp	25.6%+0.6pp	25.0%+8.5pp	16.5%-12.6pp	29.1%
Operating Margin	-92.3%+8.9pp	-101.1%+11.7pp	-112.8%+1041.7pp	-1154.5%-764.4pp	-390.1%-229.8pp	-160.3%+328.0pp	-488.3%-278.6pp	-209.6%
Net Margin	-90.4%+8.4pp	-98.9%+6.6pp	-105.4%+1041.4pp	-1146.8%-1152.8pp	6.0%+158.0pp	-151.9%+329.3pp	-481.3%-279.8pp	-201.4%
Return on Equity	-754.7%-649.4pp	-105.3%-37.1pp	-68.2%+396.8pp	-464.9%-465.4pp	0.5%+13.9pp	-13.4%+21.8pp	-35.2%-23.1pp	-12.0%
Return on Assets	-5.1%-0.4pp	-4.7%+0.3pp	-5.1%+44.4pp	-49.5%-49.7pp	0.2%+4.4pp	-4.2%+7.3pp	-11.5%-6.8pp	-4.7%
Current Ratio	5.15-1.1	6.24-0.7	6.92+0.2	6.68-0.8	7.48-2.3	9.74+1.7	8.01-1.3	9.28
Debt-to-Equity	145.59+124.3	21.25+8.8	12.42+4.0	8.39+6.9	1.49-0.7	2.20+0.1	2.06+0.5	1.57
FCF Margin	-44.6%+4.2pp	-48.9%+26.4pp	-75.3%+47.1pp	-122.3%-40.1pp	-82.3%+33.5pp	-115.7%+39.1pp	-154.8%+50.2pp	-205.0%

Similar Companies

$614.5M

$334.6M

$274.0M

$288.2M

Cytek Biosciences, Inc. CTKB

$582.3M

Frequently Asked Questions

What is Pacific Biosc's annual revenue?

Pacific Biosc (PACB) reported $160.0M in total revenue for fiscal year 2025. This represents a 3.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Pacific Biosc's revenue growing?

Pacific Biosc (PACB) revenue grew by 3.9% year-over-year, from $154.0M to $160.0M in fiscal year 2025.

Is Pacific Biosc profitable?

No, Pacific Biosc (PACB) reported a net income of -$546.4M in fiscal year 2025, with a net profit margin of -341.5%.

What is Pacific Biosc's EBITDA?

Pacific Biosc (PACB) had EBITDA of -$171.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Pacific Biosc's gross margin?

Pacific Biosc (PACB) had a gross margin of 28.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Pacific Biosc's operating margin?

Pacific Biosc (PACB) had an operating margin of -346.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Pacific Biosc's net profit margin?

Pacific Biosc (PACB) had a net profit margin of -341.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Pacific Biosc's return on equity (ROE)?

Pacific Biosc (PACB) has a return on equity of -10214.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Pacific Biosc's free cash flow?

Pacific Biosc (PACB) generated -$113.9M in free cash flow during fiscal year 2025. This represents a 46.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Pacific Biosc's operating cash flow?

Pacific Biosc (PACB) generated -$111.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Pacific Biosc's total assets?

Pacific Biosc (PACB) had $784.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Pacific Biosc's capital expenditures?

Pacific Biosc (PACB) invested $2.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Pacific Biosc spend on research and development?

Pacific Biosc (PACB) invested $97.3M in research and development during fiscal year 2025.

How many shares does Pacific Biosc have outstanding?

Pacific Biosc (PACB) had 302M shares outstanding as of fiscal year 2025.

What is Pacific Biosc's current ratio?

Pacific Biosc (PACB) had a current ratio of 5.15 as of fiscal year 2025, which is generally considered healthy.

What is Pacific Biosc's debt-to-equity ratio?

Pacific Biosc (PACB) had a debt-to-equity ratio of 145.59 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Pacific Biosc's return on assets (ROA)?

Pacific Biosc (PACB) had a return on assets of -69.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Pacific Biosc's cash runway?

Based on fiscal year 2025 data, Pacific Biosc (PACB) had $63.7M in cash against an annual operating cash burn of $111.2M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Pacific Biosc's Piotroski F-Score?

Pacific Biosc (PACB) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Pacific Biosc's earnings high quality?

Pacific Biosc (PACB) has an earnings quality ratio of 0.20x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Pacific Biosc cover its interest payments?

Pacific Biosc (PACB) has an interest coverage ratio of -79.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Pacific Biosc?

Pacific Biosc (PACB) scores 23 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.